Shilpa Medicare
Market cap ₹17,902 Cr
- P/E
- 53.59
- Day range
- ₹906.10 – ₹942.70
- 52-week range
- ₹259.50 – ₹1,095.00
- Volume
- 3.95 L
- Open
- ₹919.85
- Prev close
- ₹917.30
Latest results · Q2 FY27(consolidated)Revenue ₹529 Cr+43.0%Profit ₹79 Cr+79.7%Margin 15.0%YoY vs the same quarter last year
2 red flags to read up on
- high
Under Additional surveillance (ASM)
The exchange has put this stock under Additional surveillance (ASM), Stage I · 18 Nov 2026
- medium
Promoter holding falling
40.13%, down 4.10 pts since 2025-09-30 · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
SHILPAMED in NSE indices and F&O
Research profile
Composite 57 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.9%
- Graham no.
- ₹224.92
- vs Graham
- -75.4%
- ROE ÷ P/B
- 1.5%
- 12-1 mom.
- +145.0%
- Return / vol
- 3.31
- Magic Formula
- #536
- Piotroski
- 5/6
- FCF yield
- -0.2%
- PEG
- 0.67
Appears in 13 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Shilpa MedicareSHILPAMED | ₹17,902 Cr | 53.59 | 6.65 | 9.8% | 11.0% | 27.0% | 0.24 | +43.0% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 3h agoHeadlines about Shilpa Medicare from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 57.4
- Price / Book
- 6.49
- ROE (FY26)
- 9.8%
- ROCE (latest year)
- 11%
- Dividend yield
- 0.06%
Moving averages (NSE)
- 20-day
- ₹923.55
- Price below
- 50-day
- ₹965.58
- Price below
- 200-day
- ₹622.3
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- FII
- DII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 3 Oct 2025: earlier bars are per pre-bonus share.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 287 | 292 | 293 | 344 | 319 | 331 | 321 | 370 | 410 | 437 | 466 | 529 |
| Expenses | 222 | 222 | 222 | 258 | 239 | 252 | 231 | 262 | 296 | 317 | 330 | 387 |
| Operating Profit | 65 | 70 | 70 | 86 | 81 | 79 | 91 | 108 | 114 | 120 | 136 | 142 |
| OPM % | 23% | 24% | 24% | 25% | 25% | 24% | 28% | 29% | 28% | 27% | 29% | 27% |
| Other Income | 2 | 9 | 10 | 5 | 2 | -21 | 6 | 2 | -13 | 45 | 9 | 8 |
| Interest | 26 | 24 | 24 | 26 | 12 | 14 | 19 | 16 | 11 | 14 | 12 | 13 |
| Depreciation | 27 | 27 | 27 | 28 | 29 | 29 | 29 | 30 | 30 | 31 | 35 | 34 |
| Profit before tax | 14 | 28 | 29 | 37 | 42 | 15 | 50 | 64 | 61 | 120 | 98 | 104 |
| Tax % | 67% | 12% | 51% | 51% | 24% | 5% | 5% | 32% | 27% | 10% | -3% | 24% |
| Net Profit | 5 | 24 | 14 | 18 | 32 | 15 | 47 | 44 | 45 | 108 | 101 | 79 |
| EPS in Rs | ₹0.26 | ₹1.41 | ₹0.72 | ₹0.92 | ₹1.62 | ₹0.74 | ₹2.40 | ₹2.25 | ₹2.28 | ₹5.51 | ₹5.16 | ₹4.05 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+35 days since Mar 2021
-136 days since Mar 2021
+22 days since Mar 2021
-124 days since Mar 2021
-21 days since Mar 2021
Strengths, risks & growth
Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics. [1]
Strengths
- Company is expected to give good quarter
Risks
- Stock is trading at 6.66 times its book value
- The company has delivered a poor sales growth of 11.3% over past five years.
- Company has a low return on equity of 5.51% over last 3 years.
- Promoter holding has decreased over last 3 years: -9.88%
Compounded Sales Growth
- 10 Years
- +8%
- 5 Years
- +11%
- 3 Years
- +14%
- TTM
- +37%
Compounded Profit Growth
- 10 Years
- +8%
- 5 Years
- +18%
- 3 Years
- +109%
- TTM
- +103%
Stock Price CAGR
- 10 Years
- +13%
- 5 Years
- +27%
- 3 Years
- +71%
- 1 Year
- +150%
Return on Equity
- 10 Years
- +6%
- 5 Years
- +4%
- 3 Years
- +6%
- Last Year
- +9%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 40.13% | 40.13% | 40.13% | 40.13% | 0.00 pp |
| FII | 10.97% | 11.07% | 11.39% | 12.11% | +0.72 pp |
| DII | 8.34% | 8.58% | 8.05% | 8.26% | +0.21 pp |
| Public | 40.56% | 40.21% | 40.42% | 39.49% | -0.93 pp |
Filed with NSE for Sept 2026: promoters 40.13%, public 59.87%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 4.20% (-0.01 pp)- Promoters40.1%
- Foreign institutions12.1%
- Mutual funds4.2%
- Insurance2.6%
- Other domestic institutions1.5%
- Retail16.9%
- Others22.6%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Bandhan Small Cap Fund | 1.15% | 0.59% | +0.16 pp |
| ICICI Pru ELSS-Tax Saver Fund | 0.98% | 1.31% | +0.43 pp |
| HDFC Pharma and Healthcare Fund | 0.60% | 2.92% | +0.68 pp |
| Aditya Birla SL Small Cap Fund | 0.33% | 1.01% | +0.43 pp |
| Union Small Cap Fund | 0.28% | 1.88% | +1.88 pp |
Scorecard
- Performance
- High
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Avg
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026. Adjusted for 1 corporate action.
Risk
- Volatility (1Y)
- 42.1%
- Downside volatility
- 36.0%
- Worst 5% of days
- 3.9%
- Average of that tail
- 4.9%
- Max drawdown (1Y)
- 36.2%
- Below its peak
- 14.8%
Against the market
- Beta vs Nifty 50
- 0.78
- Correlation
- 0.25
- Relative strength (3M)
- +9.2%
- ATR (14)
- 5.5%
Return
- Return 1M
- -2.4%
- Return 3M
- +13.1%
- Return 6M
- +92.2%
- Return 1Y
- +139.2%
- vs 200-day average
- +47.1%
Momentum
- RSI (14)
- 45.1
- MACD histogram
- 0.53
- Stochastic %K
- 27.2
- ADX (14)
- 19.5
- +DI / −DI
- 17.6 / 21.9
- Money flow index
- 50.8
Participation
- Delivery (20d avg)
- 43.5%
- vs its 60-day baseline
- +1.0 pts
- Volume vs 20-day
- -0.9σ
- Close vs day's VWAP
- -0.9%
- 52-week position
- 80 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
5 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — passed
- Free cash flow
- -₹28 Cr
- FCF yield
- -0.2%
- Cash conversion
- 1.41
- Accruals ratio
- -0.027
- Net debt
- ₹621 Cr
- Net debt / equity
- 0.23
- EV / sales
- 10.08
- PEG
- 0.67
- Capex intensity
- 24.1%
- Revenue CAGR
- 36.7%
- Profit CAGR
- 209.7%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Alpesh Maheshkumar Dalal KMP · Market Sale | Sell | 4,000 | ₹42.0 L | 29 Sept 2026 |
Alpesh Maheshkumar Dalal KMP · Market Sale | Sell | 4,000 | ₹42.0 L | 29 Sept 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividendNot available — not reported in this filing
Dividend - Re 0.60 Per Share
4 Sept 2026ex-date - bonusNot available — not reported in this filing
Bonus 1:1
3 Oct 2025ex-date - dividendNot available — not reported in this filing
Dividend - Re 1 Per Share
17 Sept 2025ex-date - otherNot available — not reported in this filing
Annual General Meeting
6 Sept 2024ex-date - otherNot available — not reported in this filing
Annual General Meeting
22 Sept 2023ex-date - dividend₹1.10
Annual General Meeting/Dividend - Rs 1.10 Per Share
19 Sept 2022ex-date - otherNot available — not reported in this filing
Annual General Meeting
20 Sept 2021ex-date - dividend₹1.10
Dividend - Rs 1.10 Per Share
20 Sept 2021ex-date - dividend₹1.10
Interim Dividend - Rs 1.10 Per Share
16 Mar 2020ex-date - dividend₹1.00
Annual General Meeting/Dividend - Rs 1 Per Share
12 Sept 2019ex-date - otherNot available — not reported in this filing
Annual General Meeting
6 Sept 2018ex-date - dividendNot available — not reported in this filing
Interim Dividend Re 0.70 Per Share (Purpose Revised)
1 Mar 2018ex-date - otherNot available — not reported in this filing
Annual General Meeting
21 Sept 2017ex-date - dividendNot available — not reported in this filing
Interim Dividend Re 0.60 Per Share
21 Mar 2017ex-date - otherNot available — not reported in this filing
Annual General Meeting
20 Sept 2016ex-date - dividendNot available — not reported in this filing
Interim Dividend - Re 0.60/- Per Share (Purpose Revised)
28 Mar 2016ex-date - splitNot available — not reported in this filing
Face Value Split (Sub-Division) - From Rs 2/- Per Share To Re 1/- Per Share
6 Nov 2015ex-date - dividend₹1.10
Annual General Meeting/ Dividend - Rs 1.10/- Per Share
16 Sept 2015ex-date - dividendNot available — not reported in this filing
Annual General Meeting / Dividend - Re 1/- Per Share
11 Sept 2014ex-date - bonusNot available — not reported in this filing
Annual General Meeting / Dividend - Rs 1.30/- Per Share / Bonus 1:2
16 Jul 2013ex-date - dividend₹1.30
Annual General Meeting / Dividend - Rs 1.30/- Per Share / Bonus 1:2
16 Jul 2013ex-date
Company announcements
Europe GMP approval of Shilpa Medicare Limited. Unit 4, Jadcherla, Telangana.
Compliance Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 26, 2026 for Ramakant Innani & Others
Intimation of Closure of Trading Window
Assignment of ESG Ratings by CRISIL ESG Ratings
Investors/Analysts meet
USFDA Inspection of Shilpa Medicare Limited at Unit VII, Analytical Services Division, Hyderabad.
Submission of Scrutinizers Report on 39th AGM Resolutions along with Voting Results
Shilpa Medicare's Novel Complex Injectable OERIS (Ondansetron Extended - Release Injection, 100 mg/mL) receives final approval from Subject Expert Committee (SEC) for grant of marketing ....
Proceedings of 39th Annual General Meeting.
Initiation of NCLT Order on FTF Pharma Private Limited, a Wholly Owned Subsidiary of Shilpa Medicare Limited.
Dispatch of letter to shareholders whose e-mail addresses are not registered with Company/ Registrar & Transfer Agent/ Depository Participants.
Disclosure under Reg.30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
Dividend Update
Newspaper Publication
Filed with BSE (scrip 530549); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Regulatory orders
- Adjudication order
Adjudication Order in respect of Shilpa Medicare Limited
30 Jun 2022Read on SEBI - Order
Consent Order on the application submitted by Shri Avinash P. Bhandari in the matter of Shilpa Medicare Ltd
15 Dec 2009Read on SEBI - Order
Consent Order on the application submitted by Shri Pushparaj M. Bhandari in the matter of Shilpa Medicare Ltd
15 Dec 2009Read on SEBI - Order
Consent Order in respect of Shri Pramod Kasat in the matter of Shilpa Medicare Ltd
30 Nov 2009Read on SEBI
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlides
- Feb 2026TranscriptSlidesRecording
- Feb 2026Slides
- Nov 2025TranscriptSlides
Credit ratings
- Rating update · 6 Jul from fitch
- Rating update · 1 Jul 2025 from fitch
- Rating update · 2 Jul 2024 from fitch
- Rating update · 23 Nov 2023 from fitch
- Rating update · 22 Sep 2023 from fitch
- Rating update · 25 Jul 2023 from fitch
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 5 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Shilpa Medicare: common questions
Answered from the figures on this page.